Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC

​

Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to non-small cell lung cancer (NSCLC) patients.

The post Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.